IBDEI0AL ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4737,1,2,0)
 ;;=2^97598
 ;;^UTILITY(U,$J,358.3,4737,1,3,0)
 ;;=3^DEBRIDE,OPEN WOUND EA ADDL 20SQ CM
 ;;^UTILITY(U,$J,358.3,4738,0)
 ;;=97610^^23^304^3^^^^1
 ;;^UTILITY(U,$J,358.3,4738,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4738,1,2,0)
 ;;=2^97610
 ;;^UTILITY(U,$J,358.3,4738,1,3,0)
 ;;=3^LOW FREQ,NON-THERM US W/ WOUND ASSESS
 ;;^UTILITY(U,$J,358.3,4739,0)
 ;;=97602^^23^304^8^^^^1
 ;;^UTILITY(U,$J,358.3,4739,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4739,1,2,0)
 ;;=2^97602
 ;;^UTILITY(U,$J,358.3,4739,1,3,0)
 ;;=3^REM OF DEVITAL TISS NON-SELECT
 ;;^UTILITY(U,$J,358.3,4740,0)
 ;;=E11.9^^24^305^86
 ;;^UTILITY(U,$J,358.3,4740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4740,1,3,0)
 ;;=3^Diabetes Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,4740,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,4740,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,4741,0)
 ;;=E10.9^^24^305^52
 ;;^UTILITY(U,$J,358.3,4741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4741,1,3,0)
 ;;=3^Diabetes Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,4741,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,4741,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,4742,0)
 ;;=E11.65^^24^305^68
 ;;^UTILITY(U,$J,358.3,4742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4742,1,3,0)
 ;;=3^Diabetes Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,4742,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,4742,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,4743,0)
 ;;=E11.21^^24^305^57
 ;;^UTILITY(U,$J,358.3,4743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4743,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diab Nephropathy
 ;;^UTILITY(U,$J,358.3,4743,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,4743,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,4744,0)
 ;;=E11.22^^24^305^54
 ;;^UTILITY(U,$J,358.3,4744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4744,1,3,0)
 ;;=3^Diabetes Type 2 w/ Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,4744,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,4744,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,4745,0)
 ;;=E11.29^^24^305^71
 ;;^UTILITY(U,$J,358.3,4745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4745,1,3,0)
 ;;=3^Diabetes Type 2 w/ Kidney Complications NEC
 ;;^UTILITY(U,$J,358.3,4745,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,4745,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,4746,0)
 ;;=E11.321^^24^305^72
 ;;^UTILITY(U,$J,358.3,4746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4746,1,3,0)
 ;;=3^Diabetes Type 2 w/ Mild Nonprlf Diab Rtnop w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,4746,1,4,0)
 ;;=4^E11.321
 ;;^UTILITY(U,$J,358.3,4746,2)
 ;;=^5002634
 ;;^UTILITY(U,$J,358.3,4747,0)
 ;;=E11.329^^24^305^73
 ;;^UTILITY(U,$J,358.3,4747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4747,1,3,0)
 ;;=3^Diabetes Type 2 w/ Mild Nonprlf Diab Rtnop w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,4747,1,4,0)
 ;;=4^E11.329
 ;;^UTILITY(U,$J,358.3,4747,2)
 ;;=^5002635
 ;;^UTILITY(U,$J,358.3,4748,0)
 ;;=E11.331^^24^305^74
 ;;^UTILITY(U,$J,358.3,4748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4748,1,3,0)
 ;;=3^Diabetes Type 2 w/ Moderate Nonprlf Diab Rtnop w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,4748,1,4,0)
 ;;=4^E11.331
 ;;^UTILITY(U,$J,358.3,4748,2)
 ;;=^5002636
 ;;^UTILITY(U,$J,358.3,4749,0)
 ;;=E11.339^^24^305^75
 ;;^UTILITY(U,$J,358.3,4749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4749,1,3,0)
 ;;=3^Diabetes Type 2 w/ Moderate Nonprlf Diab Rtnop w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,4749,1,4,0)
 ;;=4^E11.339
 ;;^UTILITY(U,$J,358.3,4749,2)
 ;;=^5002637
 ;;^UTILITY(U,$J,358.3,4750,0)
 ;;=E11.341^^24^305^80
 ;;^UTILITY(U,$J,358.3,4750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4750,1,3,0)
 ;;=3^Diabetes Type 2 w/ Severe Nonprlf Diab Rtnop w/ Macular Edema
